Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

Abstract Introduction Achievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radiographic (nr) axSpA, during certolizumab pegol (CZP...

Cijeli opis

Bibliografski detalji

Glavni autori:	Robert Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, Lianne S. Gensler
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2020-06-01
Serija:	Rheumatology and Therapy
Teme:	Axial spondyloarthritis Clinical remission Early disease TNF inhibitor
Online pristup:	https://doi.org/10.1007/s40744-020-00214-7
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!